-+ 0.00%
-+ 0.00%
-+ 0.00%

TUHURA BIOSCIENCES RECEIVED FDA ORPHAN DRUG DESIGNATION FOR IFX-2.0 FOR THE TREATMENT OF STAGE IIB TO STAGE IV CUTANEOUS MELANOMA

Reuters·02/02/2026 12:45:00

Please log in to view news